Results from a phase III trial demonstrated the clinical benefit of using PD-1 inhibitor Libtayo (cemiplimab), in combination with a physician’s choice of platinum-doublet chemotherapy, in the treatment of patients with locally advanced or metastatic non-small cell lung cancer, irrespective of histology and across all PD-L1 expression levels.
When President Donald Trump on Feb. 3 signed H.R.7148, a package funding most of the federal government through FY26, many in oncology released a long-held sigh of relief.
